Benefits
Body fat: one small 21 day trial in athletes
Alpha-2 adrenergic receptors are found in higher numbers in abdominal, hip and thigh fat, and blocking them is the proposed reason yohimbine might affect those areas. That is a laboratory explanation, not something the cited human research measured. The only human trial cited here gave 20 mg a day to 20 professional male soccer players for 21 days. Their body fat fell from 9.3 percent to 7.1 percent while placebo did not change, but the same paper reported no significant change in body mass or muscle mass. Twenty already lean male athletes over three weeks is a very small and very short study, and it says nothing about weight loss in ordinary adults.
What the erectile dysfunction drug research shows
Both meta-analyses cited on this page are prescription drug research in men diagnosed with erectile dysfunction: a 1998 review in the Journal of Urology and a 2021 review in the Turkish Journal of Urology. In the United States, yohimbine hydrochloride is a prescription medicine (Yocon) for that indication, and PDE5 inhibitors have largely replaced it. Erectile dysfunction is a medical condition that can be an early sign of heart disease or diabetes, so it needs a doctor rather than a bark supplement. Results from prescription drug trials also do not transfer to over the counter yohimbe products, whose yohimbine content varies widely.
Athletic performance: the cited trial found no effect
This is a proposed mechanism, not a measured result. The only exercise study cited on this page, in 20 professional soccer players taking 20 mg a day for 21 days, stated plainly that there were no changes in exercise performance indicators within or between the yohimbine and placebo groups. Claims that yohimbine improves focus, training drive or fat burning during fasted training are not supported by anything cited here.
Mechanism of action
Alpha-2 adrenergic receptor antagonism
Yohimbine competitively blocks alpha-2 adrenergic receptors on adipocytes — receptors that normally inhibit lipolysis when activated by catecholamines. Alpha-2 receptors are more concentrated in abdominal and thigh fat, so blocking them is the proposed reason yohimbine could affect those areas. This is laboratory and pharmacology reasoning, and the human trials cited here did not test it.
Presynaptic alpha-2 autoreceptor blockade
By blocking presynaptic alpha-2 autoreceptors on noradrenergic neurons, yohimbine reduces the normal feedback that limits norepinephrine release, which increases nervous system stimulation. This is also what drives its side effects, including raised blood pressure, fast heartbeat and anxiety.
Serotonin receptor modulation
Yohimbine is also a weak serotonin 5-HT2 receptor antagonist, which may contribute to the anxiety and agitation reported at higher doses.
Clinical trials
Randomized, double-blind, placebo-controlled trial of yohimbine (20 mg a day) versus placebo in 20 professional male soccer players for 21 days, published in Research in Sports Medicine in 2006. The sample is very small and the study lasted only three weeks.
20 professional male soccer players, already lean. 21 day intervention. No women and no ordinary or overweight adults were studied.
Body fat percentage fell from 9.3 percent to 7.1 percent with yohimbine and did not change on placebo. The authors also reported no statistically significant changes in body mass or muscle mass, and no changes in exercise performance indicators within or between groups. The paper noted no side effects, but 20 people over 21 days is far too small and too short to detect the known cardiovascular risks of yohimbine.
Systematic reviews and meta-analyses of randomized trials of prescription yohimbine in men diagnosed with erectile dysfunction (Journal of Urology 1998; Turkish Journal of Urology 2021).
Men diagnosed with erectile dysfunction, a medical condition. No healthy men and no users of yohimbe bark supplements were studied.
These reviews found prescription yohimbine performed better than placebo in men being treated for erectile dysfunction. This is drug research for a medical condition, not a benefit claim for a supplement, and it shows nothing about libido, energy or fat loss in healthy people. Anyone with erectile dysfunction should see a doctor, since it can be an early warning sign of heart disease or diabetes. PDE5 inhibitors have largely replaced yohimbine.